By Sindhu Sundar ( March 24, 2015, 7:57 PM EDT) -- Otsuka Pharmaceutical Co. slammed the U.S. Food and Drug Administration Tuesday for expanding the scope of its antipsychotic drug Abilify to treat Tourette's syndrome in patients of all ages rather than only in children, calling it a ploy to admit generic versions when the company's patent expires next month....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.